Alerts
FDA Told a Promising ADC: Not Yet.
Merck and Daiichi Sankyo have withdrawn their U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA concluded the Phase II evidence was insufficient. The drug is not dead. The evidentiary shortcut is.
Ebola Modelling Shows the Outbreak May Be Bigger Than the Count
Court Fight Over ACIP Turns Vaccine Advice Into an Access Risk
Surviving Cancer Is Not the Same as Being Recovered
Tourette Care May Finally Get a New FDA Test
Hantavirus Quarantine Turns Travel Health Into a Civil-Liberties Test
Narcolepsy Treatment Starts Targeting the Cause
Infant Formula Botulism Turns Food Safety Into a Baby-Safety Emergency
AstraZeneca’s Baxfendy opens a new front in uncontrolled hypertension, but monitoring will decide who benefits
India’s emergency price-cap rise for cisplatin and carboplatin exposes a blunt oncology truth
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.